KR20040106422A - 간암 및 다른 암 질병 치료용 에포틸론 유도체 - Google Patents

간암 및 다른 암 질병 치료용 에포틸론 유도체 Download PDF

Info

Publication number
KR20040106422A
KR20040106422A KR10-2004-7017468A KR20047017468A KR20040106422A KR 20040106422 A KR20040106422 A KR 20040106422A KR 20047017468 A KR20047017468 A KR 20047017468A KR 20040106422 A KR20040106422 A KR 20040106422A
Authority
KR
South Korea
Prior art keywords
cancer
radiotherapy
treatment
advanced
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7017468A
Other languages
English (en)
Korean (ko)
Inventor
존 데이비드 로터멜
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040106422A publication Critical patent/KR20040106422A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
KR10-2004-7017468A 2002-05-01 2003-04-30 간암 및 다른 암 질병 치료용 에포틸론 유도체 Ceased KR20040106422A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
US60/377,063 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
KR20040106422A true KR20040106422A (ko) 2004-12-17

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7017468A Ceased KR20040106422A (ko) 2002-05-01 2003-04-30 간암 및 다른 암 질병 치료용 에포틸론 유도체

Country Status (23)

Country Link
US (2) US20050282873A1 (enExample)
EP (1) EP1503756B1 (enExample)
JP (1) JP2005528414A (enExample)
KR (1) KR20040106422A (enExample)
CN (1) CN1649585A (enExample)
AT (1) ATE439130T1 (enExample)
AU (1) AU2003227702B2 (enExample)
BR (1) BR0309711A (enExample)
CA (1) CA2483826C (enExample)
CY (1) CY1109607T1 (enExample)
DE (1) DE60328772D1 (enExample)
DK (1) DK1503756T3 (enExample)
ES (1) ES2330324T3 (enExample)
IL (1) IL164783A (enExample)
MX (1) MXPA04010853A (enExample)
NO (1) NO20045249L (enExample)
NZ (1) NZ536178A (enExample)
PL (1) PL211114B1 (enExample)
PT (1) PT1503756E (enExample)
RU (1) RU2358730C2 (enExample)
SI (1) SI1503756T1 (enExample)
WO (1) WO2003092683A1 (enExample)
ZA (1) ZA200408492B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
EE04852B1 (et) * 1999-02-22 2007-06-15 Gesellschaft Fuer Biotechnologische Forschung Mbh C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物

Also Published As

Publication number Publication date
BR0309711A (pt) 2005-02-09
IL164783A (en) 2011-08-31
RU2358730C2 (ru) 2009-06-20
CA2483826C (en) 2012-04-17
MXPA04010853A (es) 2005-02-14
PL371727A1 (en) 2005-06-27
CY1109607T1 (el) 2014-08-13
DE60328772D1 (de) 2009-09-24
US20050282873A1 (en) 2005-12-22
AU2003227702A1 (en) 2003-11-17
EP1503756B1 (en) 2009-08-12
PT1503756E (pt) 2009-10-28
JP2005528414A (ja) 2005-09-22
ZA200408492B (en) 2006-09-27
NO20045249L (no) 2005-01-26
HK1073601A1 (en) 2005-10-14
ES2330324T3 (es) 2009-12-09
US20080161369A1 (en) 2008-07-03
WO2003092683A1 (en) 2003-11-13
SI1503756T1 (sl) 2010-01-29
DK1503756T3 (da) 2009-11-16
IL164783A0 (en) 2005-12-18
NZ536178A (en) 2007-10-26
EP1503756A1 (en) 2005-02-09
AU2003227702B2 (en) 2007-07-26
ATE439130T1 (de) 2009-08-15
PL211114B1 (pl) 2012-04-30
CA2483826A1 (en) 2003-11-13
CN1649585A (zh) 2005-08-03
RU2004135307A (ru) 2005-09-10

Similar Documents

Publication Publication Date Title
US20080161369A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
US12544395B2 (en) Combination compositions comprising a beta-lactamase inhibitor and uses thereof
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
EP1104297B1 (en) Compositions for the treatment of chronic lymphocytic leukemia
JP2011173928A (ja) 癌処置のためのエポチロンの使用
JP2002504511A (ja) 癌処置のためのエポチロンの使用
JP2002504511A5 (enExample)
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
MXPA06002393A (es) Tratamiento de cancer con epotilomas.
JP2005503323A5 (enExample)
JP2019525922A (ja) 癌を治療するための方法および組成物
US20230338325A1 (en) Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas
WO2022238884A1 (en) Dosing regimens
CA2501717C (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
HK1073601B (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
US11478505B2 (en) Compositions of ixabepilone
CA2530311A1 (en) Cancer treatment with epothilones
EP1671631A2 (en) Compositions for the treatment of chronic lymphocytic leukemia
OA16446A (en) Compositions comprising a PI3K inhibitor and a MEK inhibitor and their use for treating cancer.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041029

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080430

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100414

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101014

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100414

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20101115

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20101014

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120229

Appeal identifier: 2010101008731

Request date: 20101115

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20101115

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20101115

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20100614

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080430

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20110106

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20101115

Effective date: 20120229

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20120302

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20101115

Decision date: 20120229

Appeal identifier: 2010101008731